Alzamend Neuro, Inc. · NASDAQ:ALZN
Alzamend Neuro — Investor Presentation (July 2026)
29 slides from Alzamend Neuro's investor presentation, July 2026
Slide 1: Corporate Presentation – July 2026
Alzamend Neuro, Inc. – Corporate Presentation CORPORATE PRESENTATION – JULY 2026 01
Slide 2: Safe Harbor Statement
Alzamend Neuro, Inc. – Safe Harbor Statement SAFE HARBOR STATEMENT This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc. (the “Company” or “Alzamend”) contain “forward looking statements” within the meaning of Section 27A of the Secu
Slide 3: Index
Alzamend Neuro, Inc. – Index 04 INTRODUCTION OUR SCIENCE (continued) Company Overview 4-8 AL001 (LISPRO) – Phase IIA Clinical Study and Results 16-17 ALZN002 (E22W) – Phase I/IIA Clinical Study 18 09 OVERVIEW OF INDICATIONS AL001 (LISPRO) – Non-Clinical Study 19-21 Alzheimer’s Disease 09 ALZN002 (E2
Slide 4: Company Overview
Alzamend Neuro, Inc. – Company Overview NASDAQ: ALZN INDUSTRY: Biopharmaceutical SECTOR: Small Molecule / Cell Theory FOUNDED: 2016 IPO: June 15, 2021 LOCATION: Atlanta, Georgia (Corporate Headquarters) 04 Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permis
Slide 5: Lead Drug Candidate - Ionic Cocrystal of Lithium (AL001)
Alzamend Neuro, Inc. – Company Overview Cont. LEAD DRUG CANDIDATE - IONIC COCRYSTAL OF LITHIUM (AL001) POTENTIAL REPLACEMENT TO MULTIPLE INDICATIONS MARKET OPPORTUNITY MARKETED LITHIUM THERAPIES AL001 is a patented ionic cocrystal of lithium for the Phase I and IIA Studies confirmed AL001 as a
Slide 6: Reference to AL001: Current Marketed Lithium – Lithium Carbonate
Alzamend Neuro, Inc. – Company Overview Cont. Reference to AL001: Current Marketed Lithium – Lithium Carbonate Usage For BD, MDD, PTSD Challenges Published Clinical Efficacy Studies For Alzheimer’s Approved by FDA for BD and utilized off- Narrow therapeutic window Forlenza, 2011(1): Lithium si
Slide 7: Pipeline
Alzamend Neuro, Inc. – Company Overview Cont. PIPELINE FDA PRODUCT CANDIDATE INDICATION* PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL Alzheimer’s Disease Anticipate initiating a Phase II clinical study in Alzheimer’s patients in 2026 Bipolar Disorder Initiated a Phase II clinical study in BD pa
Slide 8: Company History and Current Pipeline
Alzamend Neuro, Inc. – Company Overview Cont. COMPANY HISTORY CURRENT PIPELINE Clinical-stage biopharmaceutical company dedicated to: AL001 (aka LISPRO): Researching, developing and commercializing preventions, a patented ionic cocrystal technology delivering a therapeutic treatments and cures for A
Slide 9: Alzheimer's Disease Key Statistics
Alzamend Neuro, Inc. – Overview of Alzheimer’s Disease ALZHEIMER’S DISEASE KEY STATISTICS Alzheimer’s Disease is an irreversible, progressive brain disorder that 7th leading cause of death in the United States slowly destroys memory and cognitive skills, and eventually the ability to carry out the s
Slide 10: Bipolar Disorder Key Statistics
Alzamend Neuro, Inc. – Overview of Bipolar Disorder BIPOLAR DISORDER KEY STATISTICS Bipolar Disorder is a mental illness that causes unusual shifts in a An estimated 7 Million adults in the US and over 45 Million globally person’s mood, energy, activity levels, and concentration. experience Bipolar
Slide 11: Major Depressive Disorder Key Statistics
Alzamend Neuro, Inc. – Overview of Major Depressive Disorder MAJOR DEPRESSIVE DISORDER KEY STATISTICS Major Depressive Disorder “(MDD)”, commonly known as clinical An estimated 21 Million adults in U.S. had at least one major depression, is one of the most common mental disorders worldwide. depressi
Slide 12: Post-Traumatic Stress Disorder Key Statistics
Alzamend Neuro, Inc. – Overview of Post-Traumatic Stress Disorder POST-TRAUMATIC STRESS DISORDER KEY STATISTICS PTSD is a mental and behavioral disorder that can develop because About 5 out of every 100 adults (or 5%) in the U.S. has PTSD in any of exposure to a traumatic event, such as sexual assau
Slide 13: Scientific Overview: AL001 and ALZN002
Alzamend Neuro, Inc. – Scientific Overview AL001 ALZN002 Use of patented ionic cocrystal technology delivering a therapeutic A patented method using a mutant peptide sensitized cell as a cell- combination of Lithium, Proline, and Salicylate based therapeutic vaccine that reduces beta-amyloid plaque
Slide 14: AL001 Phase I Trial
Alzamend Neuro, Inc. – Our Science - Clinical AL001 Phase I Trial STUDY NO. AL001-ALZ01 (US) A randomized, balanced, Phase I, single-dose, open-label, two-treatment, two- period, two sequence, crossover, relative bioavailability study to investigate lithium STUDY TITLE pharmacokinetics and safety of
Slide 15: Safety/Tolerability: Primary Endpoint Met
Alzamend Neuro, Inc. – Select Results from Phase I Trial SAFETY/TOLERABILITY: PRIMARY ENDPOINT MET AL001 was shown to be safe and well-tolerated in healthy adult subjects No serious adverse events and no deaths were reported during the trial The safety profiles of both AL001 and the marketed l
Slide 16: AL001 Phase IIA Trial
Alzamend Neuro, Inc. – Our Science - Clinical AL001 Phase IIA Trial STUDY NO. AL001-ALZ02 (US) A Multiple-dose, Steady-state, Double-blind, Ascending Dose Safety, Tolerability, STUDY TITLE Pharmacokinetic Study of AL001 in Patients with Mild to Moderate Alzheimer’s Disease and Healthy Adult Subjects
Slide 17: Identify Maximum Tolerated Dose: Established
Alzamend Neuro, Inc. – Final Results from Phase IIA Trial IDENTIFY MAXIMUM TOLERATED DOSE: ESTABLISHED Identified dose of lithium at a lithium carbonate equivalent dose of 240 mg 3-times a day (“TID”), is designed to be unlikely to require lithium TDM No serious adverse events and no deaths were
Slide 18: ALZN002 Phase I/IIA Trial
Alzamend Neuro, Inc. – Our Science - Clinical ALZN002 Phase I/IIA Trial STUDY No. ALZN002-01 (US) A Randomized, Double-blind, Placebo-controlled, Parallel group, Phase I/IIA Study to Assess the Safety, Tolerability, and Efficacy of Autologous Amyloid Beta STUDY TITLE Mutant Peptide-Pulsed Dendritic
Slide 19: Non-Clinical - AL001 (aka LISPRO)
Alzamend Neuro, Inc. – Non-Clinical - AL001 (aka LISPRO) Narrow therapeutic window AL001 is a patented ionic cocrystal technology delivering a that requires regular blood therapeutic combination of lithium, salicylate, and proline monitoring of plasma lithium AL001 exhibits improved non-clinic
Slide 20: Results of Our Preclinical Studies, May 2016 to June 2017
Alzamend Neuro, Inc. – Non-Clinical - AL001 (aka LISPRO) THE RESULTS OF OUR PRECLINICAL STUDIES, CONDUCTED FROM MAY 2016 TO JUNE 2017, ARE SUMMARIZED BELOW: AL001 had no effect on renal COX2 activity (Tg-Ctrl vs. AL001: p > 0.05), a biomarker of renal toxicity, while markedly reducing abnormal bio
Slide 21: The Results
Alzamend Neuro, Inc. – Non-Clinical - AL001 (aka LISPRO) THE RESULTS No significant differences in body weight, brain, heart, lung, spleen, liver or kidney were found between lithium treated and untreated APPSWE/PS1dE9 cohorts (Tg-Ctrl vs. AL001: p > 0.05). AL001 treatment improved cognitive fun
Slide 22: The Results: Non-Clinical Overview of ALZN002
Alzamend Neuro, Inc. – Non-Clinical - Overview of ALZN002 (aka E22W) THE RESULTS Mice vaccinated with various mutated Aß 1-42 peptides induce antibody responses after two inoculations, while no antibody can be detected in the control group (FIG. 5A). All antibodies induced by the peptide injecti
Slide 23: The Results: Non-Clinical Overview of ALZN002
Alzamend Neuro, Inc. – Non-Clinical - Overview of ALZN002 (aka E22W) THE RESULTS There is no antibody production after two injections of DCs sensitized with Wild-Type Aß peptide (PWT). However, all other groups that received DCs sensitized with mutant Aß can induce antibody response even with only
Slide 24: Neuro's Intellectual Property (Licensed Patents)
Alzamend Neuro, Inc. – Alzamend Neuro’s Intellectual Property (Licensed Patents) THERAPUTIC EXPIRATION TITLE OF PATENT PATENT TYPE DATE FILED DATE ISSUED PATENT # DRUG DATE Lithium Cocrystals and an Additional Neuropsychiatric AL001 Method of use 05.21.2016 03.28.2017 05.21.2036 9,603,869 Agent for
Slide 25: Market Opportunity for AL001 and ALZN002
Alzamend Neuro, Inc. – Market Opportunity for AL001 and ALZN002 PATIENT POPULATION UNITED STATES GLOBAL (US INCLUDED) SOURCES Major Depressive Disorder: MDD 21 Million 280 Million 1. https://www.nimh.nih.gov/health/statistics/major-depression 2. https://www.who.int/news-room/fact-sheets/detail/dep
Slide 26: Meet the Leadership Team
Alzamend Neuro, Inc. – Leadership MEET THE LEADERSHIP TEAM STEPHAN JACKMAN HENRY NISSER Chief Executive Officer and Director Executive Vice President, Counsel & Director 20+ years multi-industry experience, 20+ years experience, U.S. securities specialized in Biotech and compliance, M&A, equity/debt
Slide 27: Alzamend Scientific Advisory Board
Alzamend Neuro, Inc. – Scientific Advisory Board ALZAMEND SCIENTIFIC ADVISORY BOARD Thomas M. Wisniewski, M.D. Director, NYU Langone’s Pearl I. Barlow Center for Memory Evaluation and Treatment 300+ Peer-Reviewed Medical Journal Publications (19 U.S. Patents Issued) Leads a Research Laboratory Conti
Slide 28: Alzamend Board of Directors
Alzamend Neuro, Inc. – Board of Directors ALZAMEND BOARD OF DIRECTORS WILLIAM B. HORNE Chairman of Alzamend Chief Executive Officer of Ault Alliance 25+ years Financial Industry experience, prior “Big 4” auditor and healthcare executive STEPHAN JACKMAN JEFFREY ORAM Chief Executive Officer and Direct
Slide 29: Contact Us
Alzamend Neuro, Inc. – Contact Us CONTACT US 3480 Peachtree Road NE, www.alzamend.com 2nd Floor, Suite 103 Atlanta, GA 30326 +1 (844) 722 - 6333 Info@alzamend.com 29 Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission.